Rituxan for Opsoclonus Myoclonus Syndrome – pro
Rituxan has been reported to alleviate the myoclonus opsoclonus syndrome in case reports and series. Presumably there is an immunologic mechanism underlying this observation. Approximately 50 % of patients with OMS have an associated neuroblastoma or associated infections have also been reported. There is no specific diagnostic biomarker for OMS. Other treatments include as ACTH, corticosteroids, cyclophosphamide and/or intravenous immunoglobulin,
Read more